Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{158529,
        author = {Loganathan A and NALLA KUMAR P and PONNILAVARASAN I and VIGNESH S and GOWTHAM D},
        title = {A REVIEW ON METHOD DEVELOPMENT AND VALIDATION OF FAVIPIRAVIR BULK AND THEIR TABLET DOSAGE FORM},
        journal = {International Journal of Innovative Research in Technology},
        year = {},
        volume = {9},
        number = {9},
        pages = {615-620},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=158529},
        abstract = {Favipiravir is an antiviral drug that was initially developed for influenza by Toyama Chemical, which has recently garnered much attention, especially in India, is an anti-viral drug originally designed for influenza, called Favipiravir. In this article, we have tried to provide a complete, evidence-based review of this drug in the perspective of the present pandemic to give further details about its role in the management of COVID-19. Favipiravir is a very widely used pharmaceutical, consequently it has been detected in the water system. The aim of this review is to focus on update of determination of  Favipiravir in bulk and in pharmaceutical preparations using chromatographic and spectrophotometric methods. Favipiravir are estimated by RP-HPLC, UV, HPLC, RP-HPLC,UPLC, methods. For subjective and quantitative estimation of  Favipiravir these diagnostic techniques can be utilized. This review provides detailed information on separation conditions for Favipiravir in the presence of drug and in presence of its degradation products. },
        keywords = {RP-HPLC, UV, RP-UPLC, NMR\LC-MS,UPLC.},
        month = {},
        }